Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia. AD is characterized by the extracellular amyloid beta (Aβ) plaques and intraneuronal deposits of neurofibrillary tangles (NFTs). Recently, as aging has become a familiar phenomenon around the world, patients with AD are increasing in number. Thus, many researchers are working toward finding effective therapeutics for AD focused on Aβ hypothesis, although there has been no success yet. In this review paper, we suggest that AD is a metabolic disease and that we should focus on metabolites that are affected by metabolic alterations to find effective therapeutics for AD. Aging is associated with not only AD but also obesity and type 2 diabetes (T2DM). AD, obesity, and T2DM share demographic profiles, risk factors, and clinical and biochemical features in common. Considering AD as a kind of metabolic disease, we suggest insulin, adiponectin, and antioxidants as mechanistic links among these diseases and targets for AD therapeutics. Patients with AD show reduced insulin signal transductions in the brain, and intranasal injection of insulin has been found to have an effect on AD treatment. In addition, adiponectin is decreased in the patients with obesity and T2DM. This reduction induces metabolic dysfunction both in the body and the brain, leading to AD pathogenesis. Oxidative stress is known to be induced by Aβ and NFTs, and we suggest that oxidative stress caused by metabolic alterations in the body induce brain metabolic alterations, resulting in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · cited 1×
“Due to aging, mitochondria can malfunction, resulting in excessive increases in oxidative stress, as well as oxidative phosphorylation, in the brain.(29) Increased mitochondrial oxidative activity demands more energy substrates to produce energy, such that there is an energy shortage in the whole body even though the…”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“Amyloid hypothesis has become the dominant model of AD pathogenesis and has guided the development of potential treatments for AD.(17) However, clinical studies have documented several inconsistencies in AD pathology.”
BackgroundIncreased oxidative stress in obesity and its impact on metabolic syndrome
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21625 · Cited by 5,508 · cited 1×
“Many studies have demonstrated that reduced insulin signals and adipokines dysregulation in T2DM patients leads to increased ROS production.(89) Furthermore, high glucose levels are able to cause oxidative stress by various mechanisms, including glucose autoxidation, polyol pathway, advanced glycation end products for…”
Background2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Adipokines in inflammation and metabolic disease
Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011) · Nature Reviews Immunology · doi:10.1038/nri2921 · Cited by 4,625 · cited 1×
“Adipokines regulate several important physiological functions: for example, appetite, satiety, energy expenditure, insulin sensitivity and secretion, glucose and lipid metabolism, fat distribution, hemostasis, blood pressure, neuroendocrine regulation, and function of the immune system.(62) In obesity, adipocytes beco…”
BackgroundHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526
Signal transduction by reactive oxygen species
Finkel, T. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201102095 · Cited by 2,322 · cited 1×
“Physiological levels of ROS/RNS play an important role in maintaining homeostasis and regulating signal transduction involved in proliferation and survival.(83) Cellular antioxidant defense mechanisms regulate ROS/RNS production to maintain proper amounts thereof in normal environments.”
BackgroundBrain energy metabolism: focus on Astrocyte-neuron metabolic cooperation
Bélanger, M., Allaman, I., & Magistretti, P. J. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.016 · Cited by 2,313
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“6% of drug candidates targeting amyloid pathways, such as beta secretase inhibitors, gamma secretase inhibitors, and Aβ itself, have failed.(18) In addition, a weak correlation between Aβ deposition and cognitive decline have been reported.”
BackgroundSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
Obesity-associated improvements in metabolic profile through expansion of adipose tissue
Kim, J.-Y., van de Wall, E., Laplante, M., Azzara, A., Trujillo, M. E., Hofmann, S. M., Schraw, T., Durand, J. L., Li, H., Li, G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31021 · Cited by 1,310 · cited 1×
“Overexpression of adiponectin prevents high-fat diet-induced obesity in rodents, and genetically eliminating adiponectin in obese mice facilitates increased fat in the liver.(66) Adiponectin reduces hepatic lipogenesis and increases β-oxidation through adiponectin receptor 1 (adipoR1)-mediated activation of ade-”
BackgroundCraft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158 · cited 1×
“Also, increasing evidence has shed light on cellular insulin resistance or insulin insufficiency in the brains of AD patients, including those without having diabetes, thus AD is often referred to as “type 3 diabetes”.(6) Obesity is generally defined by a body mass index (BMI) over 30 kg/m(2) (25 kg/m(2) in Korea) and…”
BackgroundIncreased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950 · cited 1×
“According to the Mayo Clinic Alzheimer Disease Patient Registry, 80% of AD patients show impairment in glucose tolerance or have diabetes.(4) Epidemiological studies have demonstrated that T2DM induces cognitive impairment and that patients with T2DM are more likely to be diagnosed with dementia by 1.”
MethodGlucose Levels and Risk of Dementia
Crane, P. K., Walker, R., Hubbard, R. A., Li, G., Nathan, D. M., Zheng, H., Haneuse, S., Craft, S., Montine, T. J., Kahn, S. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215740 · Cited by 929 · cited 1×
“Hyperglycemia has also been found to accelerate cognitive decline.(32) As the brain is likely to encounter defective insulin signaling with increasing age,(33) researchers have begun to study mechanistic links between these diseases; the most promising link has been insulin.”
BackgroundBrain Imaging in Alzheimer Disease
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875 · cited 1×
“Recently, early selective atrophy and alteration of glucose metabolism were discovered in the medial temporal lobe of patients with AD using imaging tools.(21) In addition, in Alzheimer’s disease, degeneration of the basal forebrain cholinergic neurons and a decrease in brain glucose metabolism are characteristically…”
BackgroundAdipocytokines in Obesity and Metabolic Disease
Cao, H. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0339 · Cited by 705
Intranasal insulin improves memory in humans
Benedict, C., Hallschmid, M., Hatke, A., Schultes, B., Fehm, H. L., Born, J., & Kern, W. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2004.04.003 · Cited by 699
Amyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587 · cited 1×
“In turn, Aβ oligomers initiate to remove insulin receptors from plasma membranes.(49) Following these discoveries, insulin has been measured in postmortem brain tissue from AD patients, showing relatively low levels of insulin.”
BackgroundInconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
The source of cerebral insulin
Banks, W. A. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.040 · Cited by 489 · cited 1×
“Due to the large size of insulin peptide, it was thought that insulin is unable to cross the brain blood barrier (BBB), such that the brain was regarded as an insulin-independent organ.(38) However, several studies have revealed that insulin receptors are abundantly distributed throughout the brain, proposing some mec…”
BackgroundMucke, L. (2009) · Nature · doi:10.1038/461895a · Cited by 456
The role of leptin/adiponectin ratio in metabolic syndrome and diabetes
López-Jaramillo, P., Gómez-Arbeláez, D., López-López, J., López-López, C., Martínez-Ortega, J., Gómez-Rodríguez, A., & Triana-Cubillos, S. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2013-0053 · Cited by 405 · cited 1×
“Among adipokines, adiponectin has beneficial effects on patients with T2DM and has been used in T2DM treatment due to its role of increasing insulin sensitivity.(64) Adiponectin has been shown to enhance insulin sensitivity and several studies have reported the relationship between an increased prevalence of diabetes…”
BackgroundObesity, diabetes and cognitive deficit: The Framingham Heart Study
Elias, M. F., Elias, P. K., Sullivan, L. M., Wolf, P. A., & D’Agostino, R. B. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.08.019 · Cited by 395 · cited 1×
“Even when controlling for aging, studies have shown a negative correlation between BMI and global cognitive performance.(9) T2DM has also been linked to reduced cognitive function and an increased risk for developing dementia, including AD.”
BackgroundHow does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337
Giraldo, E., Lloret, A., Fuchsberger, T., & Viña, J. (2014) · Redox Biology · doi:10.1016/j.redox.2014.03.002 · Cited by 268 · cited 1×
“Aβ-induced oxidative stress disturbs cellular signaling and initiates a phosphorylation response, resulting in activated JNK, p38 MAPK, and hyperphosphorylated tau proteins in AD postmortem brains.(86) Furthermore, since Aβ is generated from the cleavage of amyloid precursor proteins, located in trans membrane, it ins…”
BackgroundEsposito, L., Raber, J., Kekonius, L., Yan, F., Yu, G.-Q., Bien-Ly, N., Puoliväli, J., Scearce-Levie, K., Masliah, E., & Mucke, L. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0482-06.2006 · Cited by 254
Impaired insulin action in the human brain: causes and metabolic consequences
Heni, M., Kullmann, S., Preissl, H., Fritsche, A., & Häring, H.-U. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.173 · Cited by 245
Fatty Acids in Energy Metabolism of the Central Nervous System
Panov, A., Orynbayeva, Z., Vavilin, V., & Lyakhovich, V. (2014) · BioMed Research International · doi:10.1155/2014/472459 · Cited by 227
Insulin Regulates Brain Function, but How Does It Get There?
Gray, S. M., Meijer, R. I., & Barrett, E. J. (2014) · Diabetes · doi:10.2337/db14-0340 · Cited by 206
Ho, L., Yemul, S., Knable, L., Katsel, P., Zhao, R., Haroutunian, V., & Pasinetti, G. M. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/321280 · Cited by 21 · cited 1×
“Following these discoveries, insulin has been measured in postmortem brain tissue from AD patients, showing relatively low levels of insulin.(50) Previously, we demonstrated that longterm high fat diet induces T2DM with insulin resistance both in the body and the brain, as well as AD pathologies, such as cognitive def…”
Background
Cited by
Alzheimer’s disease: risk factors and potentially protective measures
Silva, M. V. F., Loures, C. D. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Carvalho, M. D. G. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0524-y · Cited by 937
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
“from [65], Copyright 2017, Yonsei Univ rsity College of Medicine.”
MethodKruk, J., Aboul-Enein, H. Y., Kładna, A., & Bowser, J. E. (2019) · Free Radical Research · doi:10.1080/10715762.2019.1612059 · Cited by 284
Hussain, B., Fang, C., & Chang, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.688090 · Cited by 255
Metadata
- Authors
- Kang, S., Lee, Y.-H., & Lee, J. E.
- Venue
- Yonsei Medical Journal
- Publisher
- XMLink
- Published
- 2017
- Volume
- 58
- Issue
- 3
- Pages
- 479
- ISSN
- 0513-5796 (ISSN-L)
- 1976-2437
- OpenAlex
- W2600906879
- Cited by
- 143
- References
- 32
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.